Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Stage IB, II or IIIA non-small cell lung cancer

Adjuvant therapy

Patient must be continuing existing PBS-subsidised treatment with this drug; or

Patient must be both: (i) transitioning from existing non-PBS to PBS-subsidised supply of this drug, (ii) untreated with EGFR-TKI at the time this drug was initiated; AND

The treatment must be for the purpose of adjuvant therapy following surgical resection; AND

Patient must have evidence of an activating epidermal growth factor receptor (EGFR) gene mutation known to confer sensitivity to treatment with EGFR tyrosine kinase inhibitors in tumour material; AND

Patient must have/have had a WHO performance status score of no greater than 1 at treatment initiation with this drug; AND

The treatment must be commenced within 26 weeks of surgery; AND

The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition; AND

Patient must be undergoing treatment that does not occur beyond the following, whichever comes first: (i) the first instance of disease progression/recurrence, (ii) 3 years in total for this condition from the first administered dose; mark any remaining repeat prescriptions with the word 'cancelled'; where (i)/(ii) has occurred; AND

Must be treated by a medical practitioner; or

Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a medical practitioner, (ii) the prescription continues existing therapy with this medicine.

PBS-subsidised treatment with this drug is restricted to one line of therapy at any disease staging for NSCLC (i.e. if therapy has been prescribed for early disease, subsidy under locally advanced or metastatic disease is no longer available).